ReP USP - Resultado da busca

Artigo de periodico
High throughput assessment of biomarkers in tissue microarrays using artificial intelligence: PTEN loss as a proof-of-principle in multi-center prostate cancer cohorts (2021)
Harmon, Stephanie A.; Patel, Palak G.; Sanford, Thomas H.; Caven, Isabelle; Iseman, Rachael; Vidotto, Thiago; Picanço, Clarissa; Squire, Jeremy Andrew ; Masoudi, Samira; Mehralivand, Sherif; Choyke, Peter L.; Berman, David M.; Turkbey, Baris; Jamaspishvili, Tamara
Source: Modern Pathology. Unidade: FMRP
Subjects: ALGORITMOS, BIOMARCADORES, ESTUDOS DE COORTES, SEQUENCIAMENTO GENÉTICO, IMAGEM DIGITAL, NEOPLASIAS PROSTÁTICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HARMON, Stephanie A. et al. High throughput assessment of biomarkers in tissue microarrays using artificial intelligence: PTEN loss as a proof-of-principle in multi-center prostate cancer cohorts. Modern Pathology, v. 34, p. 478-489, 2021Tradução . . Disponível em: https://doi.org/10.1038/s41379-020-00674-w. Acesso em: 10 nov. 2024.
APA
Harmon, S. A., Patel, P. G., Sanford, T. H., Caven, I., Iseman, R., Vidotto, T., et al. (2021). High throughput assessment of biomarkers in tissue microarrays using artificial intelligence: PTEN loss as a proof-of-principle in multi-center prostate cancer cohorts. Modern Pathology, 34, 478-489. doi:10.1038/s41379-020-00674-w
NLM
Harmon SA, Patel PG, Sanford TH, Caven I, Iseman R, Vidotto T, Picanço C, Squire JA, Masoudi S, Mehralivand S, Choyke PL, Berman DM, Turkbey B, Jamaspishvili T. High throughput assessment of biomarkers in tissue microarrays using artificial intelligence: PTEN loss as a proof-of-principle in multi-center prostate cancer cohorts [Internet]. Modern Pathology. 2021 ; 34 478-489.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1038/s41379-020-00674-w
Vancouver
Harmon SA, Patel PG, Sanford TH, Caven I, Iseman R, Vidotto T, Picanço C, Squire JA, Masoudi S, Mehralivand S, Choyke PL, Berman DM, Turkbey B, Jamaspishvili T. High throughput assessment of biomarkers in tissue microarrays using artificial intelligence: PTEN loss as a proof-of-principle in multi-center prostate cancer cohorts [Internet]. Modern Pathology. 2021 ; 34 478-489.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1038/s41379-020-00674-w
Artigo de periodico
Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN) (2020)
Jamaspishvili, Tamara; Patel, Palak G; Niu, Yi; Vidotto, Thiago; Caven, Isabelle; Livergant, Rachel; Fu, Winnie; Kawashima, Atsunari; How, Nathan; Okello, John B.; Guedes, Liana B.; Ouellet, Veronique; Picanço, Clarissa; Koti, Madhuri; Reis, Rodolfo Borges dos ; Saad, Fred; Mes-Masson, Anne-Marie; Lotan, Tamara L; Squire, Jeremy Andrew ; Peng, Yingwei P.; Siemens, D. Robert; Berman, David M.
Source: JNCI: Journal of the National Cancer Institute. Unidade: FMRP
Subjects: PRÓSTATA, NEOPLASIAS, PROSTATECTOMIA, IMUNOHISTOQUÍMICA, ANÁLISE EM MICROSSÉRIES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
JAMASPISHVILI, Tamara et al. Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN). JNCI: Journal of the National Cancer Institute, v. 112, n. 11, p. 1098-1104, 2020Tradução . . Disponível em: https://doi.org/10.1093/jnci/djaa032. Acesso em: 10 nov. 2024.
APA
Jamaspishvili, T., Patel, P. G., Niu, Y., Vidotto, T., Caven, I., Livergant, R., et al. (2020). Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN). JNCI: Journal of the National Cancer Institute, 112( 11), 1098-1104. doi:10.1093/jnci/djaa032
NLM
Jamaspishvili T, Patel PG, Niu Y, Vidotto T, Caven I, Livergant R, Fu W, Kawashima A, How N, Okello JB, Guedes LB, Ouellet V, Picanço C, Koti M, Reis RB dos, Saad F, Mes-Masson A-M, Lotan TL, Squire JA, Peng YP, Siemens DR, Berman DM. Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN) [Internet]. JNCI: Journal of the National Cancer Institute. 2020 ; 112( 11): 1098-1104.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1093/jnci/djaa032
Vancouver
Jamaspishvili T, Patel PG, Niu Y, Vidotto T, Caven I, Livergant R, Fu W, Kawashima A, How N, Okello JB, Guedes LB, Ouellet V, Picanço C, Koti M, Reis RB dos, Saad F, Mes-Masson A-M, Lotan TL, Squire JA, Peng YP, Siemens DR, Berman DM. Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN) [Internet]. JNCI: Journal of the National Cancer Institute. 2020 ; 112( 11): 1098-1104.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1093/jnci/djaa032
Artigo de periodico
PTEN‐deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells (2019)
Vidotto, Thiago ; Saggioro, Fabiano Pinto ; Jamaspishvili, Tamara; Chesca, Deise Lúcia; Albuquerque, Clarissa Gondim Picanço de; Reis, Rodolfo Borges dos ; Graham, Charles H.; Berman, David M.; Siemens, D. Robert; Squire, Jeremy Andrew ; Koti, Madhuri
Source: The Prostate. Unidades: SVOI, FMRP
Subjects: PRÓSTATA, NEOPLASIAS, SISTEMA IMUNE, REGULAÇÃO GÊNICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VIDOTTO, Thiago et al. PTEN‐deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells. The Prostate, v. 79, n. 9, p. 969-979, 2019Tradução . . Disponível em: https://doi.org/10.1002/pros.23808. Acesso em: 10 nov. 2024.
APA
Vidotto, T., Saggioro, F. P., Jamaspishvili, T., Chesca, D. L., Albuquerque, C. G. P. de, Reis, R. B. dos, et al. (2019). PTEN‐deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells. The Prostate, 79( 9), 969-979. doi:10.1002/pros.23808
NLM
Vidotto T, Saggioro FP, Jamaspishvili T, Chesca DL, Albuquerque CGP de, Reis RB dos, Graham CH, Berman DM, Siemens DR, Squire JA, Koti M. PTEN‐deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells [Internet]. The Prostate. 2019 ; 79( 9): 969-979.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1002/pros.23808
Vancouver
Vidotto T, Saggioro FP, Jamaspishvili T, Chesca DL, Albuquerque CGP de, Reis RB dos, Graham CH, Berman DM, Siemens DR, Squire JA, Koti M. PTEN‐deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells [Internet]. The Prostate. 2019 ; 79( 9): 969-979.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1002/pros.23808
Artigo de periodico
Clinical implications of PTEN loss in prostate cancer (2018)
Jamaspishvili, Tamara; Berman, David M.; Ross, Ashley E.; Scher, Howard I.; Marzo, Angelo M. De; Squire, Jeremy Andrew; Lotan, Tamara L.
Source: Nature Reviews Urology. Unidade: FMRP
Subjects: PRÓSTATA, NEOPLASIAS, BIOMARCADORES, GENÉTICA MÉDICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
JAMASPISHVILI, Tamara et al. Clinical implications of PTEN loss in prostate cancer. Nature Reviews Urology, v. 15, n. 4, p. 222–234, 2018Tradução . . Disponível em: https://doi.org/10.1038/nrurol.2018.9. Acesso em: 10 nov. 2024.
APA
Jamaspishvili, T., Berman, D. M., Ross, A. E., Scher, H. I., Marzo, A. M. D., Squire, J. A., & Lotan, T. L. (2018). Clinical implications of PTEN loss in prostate cancer. Nature Reviews Urology, 15( 4), 222–234. doi:10.1038/nrurol.2018.9
NLM
Jamaspishvili T, Berman DM, Ross AE, Scher HI, Marzo AMD, Squire JA, Lotan TL. Clinical implications of PTEN loss in prostate cancer [Internet]. Nature Reviews Urology. 2018 ; 15( 4): 222–234.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1038/nrurol.2018.9
Vancouver
Jamaspishvili T, Berman DM, Ross AE, Scher HI, Marzo AMD, Squire JA, Lotan TL. Clinical implications of PTEN loss in prostate cancer [Internet]. Nature Reviews Urology. 2018 ; 15( 4): 222–234.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1038/nrurol.2018.9

USP Schools

ReP

Filtros

Authors

USP affiliated authors

Subjects

Funding Agencies

Indexado em

Non normalized affiliation